Gabriel Rubanenko, MD
Orthopaedic Surgery · Los Angeles, CANPI 1194704643
Payments from drug & device makers
Across 57 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$455
- Bioventus LLC$217
- Avanir Pharmaceuticals, Inc.$73
- IBSA Pharma Inc.$69
- Novartis$54
- Johnson & Johnson$50
- plus $196 from 7 others
What the payments were for
- Food & beverage$1,114100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 27 | $455 |
| Bioventus LLC | 9 | $217 |
| Avanir Pharmaceuticals, Inc. | 3 | $73 |
| IBSA Pharma Inc. | 4 | $69 |
| Novartis | 3 | $54 |
| Johnson & Johnson(2 entities) | 2 | $50 |
| Scilex Pharmaceuticals Inc. | 2 | $39 |
| Vivus LLC | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 1 | $29 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $23 |
| AbbVie | 1 | $23 |
| Novo Nordisk | 1 | $17 |
How this compares
$1,114 in reported general payments places this provider in the 35th percentile of 1,808 orthopaedic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 96 | $55,040 |
| Lidocaine | 52 | $5,367 |
| Celecoxib | 36 | $536 |
| Naproxen | 37 | $109 |
| Meloxicam | 65 | $105 |
| Tramadol Hcl | 73 | $105 |
| Methylprednisolone | 15 | $95 |
| Gabapentin | 19 | $91 |
| Cyclobenzaprine Hcl | 18 | $40 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Los Angeles
- Kelly VinceLos Angeles$9.6M
- Jay LiebermanLos Angeles$4.8M
- Thomas SchmalzriedLos Angeles$4M
- David ThordarsonLos Angeles$2.6M
- David SkaggsLos Angeles$2.6M
- Edward McPhersonLos Angeles$1.3M
- Andrew SpitzerLos Angeles$1.2M
- Daniel AllisonLos Angeles$1.1M
- Charles MoonLos Angeles$986K
- Justin SalimanLos Angeles$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.